prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
The aim of this Newsletter is to disseminate information on the safety and efficacy of pharmaceutical products, based on information received from our network of “drug information officers” and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from:
Quality Assurance and Safety: Medicines, PSM-HTP World Health Organization, 1211 Geneva 27, Switzerland E-mail address: firstname.lastname@example.org
This newsletter is also available on our Internet website: http://www.who.int/medicines
Further information on adverse reactions may be obtained from the WHO Collaborating Centre for International Drug Monitoring, Stora Torget 3, 753 20 Uppsala, Sweden Tel: 46-18-65.60.60 Fax: 46-18-65.60.80 E-mail: email@example.com Internet: http://www.who-umc.org
News & Issues
More definite regulatory actions have now been taken in some countries, either for specific cyclooxygenase-inhibitors or for the non-steroidal anti-inflammatory drugs as a whole; the most recent decisions are included in this issue. A list of recently prequalified drugs is also included as part of our promise to familiarize readers with the work of the WHO prequalification team.
Preparations are under way for the Twenty-eighth Annual Meeting of Representatives of National Centres participating in the WHO International Drug Monitoring Programme, to be held in Geneva, 26 - 29 September 2005. In addition to various other collaborative features, this year's meeting will include a working group exercise on patient safety, to determine how national pharmacovigilance centres could work with the World Alliance for Patient Safety. The draft agenda for the meeting is published with this edition for your information. We hope to see many of you at the meeting.
© World Health Organization 2005
All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: firstname.lastname@example.org). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: email@example.com).
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.
This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.